Temsirolimus News and Research

RSS
Temsirolimus is approved by the Food and Drug Administration (FDA) to treat advanced renal cell carcinoma (kidney cancer). Temsirolimus is also being studied in the treatment of other types of cancer. Temsirolimus is an ester analog of rapamycin. Temsirolimus binds to and inhibits the mammalian target of rapamycin (mTOR), resulting in decreased expression of mRNAs necessary for cell cycle progression and arresting cells in the G1 phase of the cell cycle. mTOR is a serine/threonine kinase which plays a role in the PI3K/AKT pathway that is upregulated in some tumors.
EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

Combination therapy does not change safety and efficacy relationship of TORISEL for advanced RCC

Combination therapy does not change safety and efficacy relationship of TORISEL for advanced RCC

Montefiore experts available to discuss cancer research at 2012 ASCO meeting

Montefiore experts available to discuss cancer research at 2012 ASCO meeting

Pfizer fails to meet primary endpoint in TORISEL Phase 3 study for advanced RCC

Pfizer fails to meet primary endpoint in TORISEL Phase 3 study for advanced RCC

FDA approves Novartis’ Afinitor for treatment of renal angiomyolipomas and TSC

FDA approves Novartis’ Afinitor for treatment of renal angiomyolipomas and TSC

Combination treatment effective against melanoma

Combination treatment effective against melanoma

Combination of cixutumumab and temsirolimus shrinks tumors in patients with Ewing's sarcoma

Combination of cixutumumab and temsirolimus shrinks tumors in patients with Ewing's sarcoma

Aberrations in translation regulators linked with hormone receptor-positive breast cancer survival

Aberrations in translation regulators linked with hormone receptor-positive breast cancer survival

Inlyta receives FDA approval for treatment of advanced kidney cancer

Inlyta receives FDA approval for treatment of advanced kidney cancer

Positive results from Puma's neratinib Phase II trials presented at CTRC-AACR San Antonio Breast Cancer Symposium

Positive results from Puma's neratinib Phase II trials presented at CTRC-AACR San Antonio Breast Cancer Symposium

Updated data from Novartis Afinitor plus everolimus Phase III study on advanced breast cancer

Updated data from Novartis Afinitor plus everolimus Phase III study on advanced breast cancer

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

Combination of Afinitor, exemestane reduces risk of breast cancer progression in women

Combination of Afinitor, exemestane reduces risk of breast cancer progression in women

Novartis Afinitor Phase III trial on tuberous sclerosis meets primary endpoint

Novartis Afinitor Phase III trial on tuberous sclerosis meets primary endpoint

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

FDA approves Novartis' Afinitor tablets for pancreatic NET treatment

FDA approves Novartis' Afinitor tablets for pancreatic NET treatment

Temsirolimus with chemotherapy may serve as promising therapy for mesothelioma

Temsirolimus with chemotherapy may serve as promising therapy for mesothelioma

Research on rare cancers

Research on rare cancers